Home › Funds › ProShares › ProShares Ultra Health Care
Fund family: ProShares · Filed by PROSHARES TRUST (CIK 1174610) · SEC series S000014253
Ticker: RXL (C000038812)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 733 with, 33 against, 0 abstentions (not counted as with management). Shareholder proposals: 14 FOR, 19 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as ProShares’s manager page (303,945 ballot items across 135 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | ProShares | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 97.5% | 715 | 91.4% | 279,029 |
| Backed environmental and social shareholder proposals at US companies | n/a | 9 | 10.6% | 4,043 |
Each ballot item this fund voted is set against the votes of the other ProShares funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most ProShares funds on all 746 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 100.0% of this fund’s 766 such votes could be given a sector.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 675 | 31 | 4.6% |
| Industrials | 74 | 1 | 1.4% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 563 | 0 |
| Say-on-Pay | 63 | 0 |
| Audit-related | 62 | 0 |
| Corporate Governance | 36 | 22 |
| Compensation | 22 | 2 |
| Capital Structure | 7 | 0 |
| Other Social Issues | 5 | 5 |
| Shareholder Rights and Defenses | 4 | 0 |
| Environment or Climate | 3 | 3 |
| Extraordinary Transactions | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $13M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $8M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $6M | 8 | 1 |
| UnitedHealth Group Incorporated | June 1, 2026 | $4M | 12 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $4M | 18 | 3 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $3M | 13 | 0 |
| Amgen Inc. | May 19, 2026 | $3M | 15 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $2M | 15 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
These funds reported the same votes as ProShares Ultra Health Care in the latest season (or all but a few items), so they share this page:
768 ballot items at 63 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, ProShares Ultra Health Care (RXL) voted at 63 shareholder meetings of 60 companies, on 768 ballot items in all. Where management made a recommendation, the fund followed it on 95.7% of the items and voted against it 33 times. Its most frequent area of disagreement was corporate governance (22 of its votes against management). It voted on 33 shareholder proposals. It voted FOR the board's own proposals more often than ProShares's funds as a whole (97.5% against 91.4%). It voted the same way as most ProShares funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ProShares’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.